Legend surges on early data for ‘in vivo’ lymphoma cell therapy

Data ReadoutpositiveKymriahPositive

AI Analysis

Summary

Legend Biotech reported early positive data for an in vivo lymphoma cell therapy that reduced or eliminated disease signs in all study recipients, positioning it as a potential competitor to Novartis' Kymriah.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Therapy reduced or eliminated disease signs in all recipients

Importance:7/10

Sentiment:

0.85

cell therapyin vivolymphomaclinical datacompetitive advantage

Related Companies

$LEGN $NVS

Read the original article

Published by BioPharma Dive on June 3, 2026 3:57 PM

Read Original